AR123138A1 - COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME - Google Patents
COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROMEInfo
- Publication number
- AR123138A1 AR123138A1 ARP210102164A ARP210102164A AR123138A1 AR 123138 A1 AR123138 A1 AR 123138A1 AR P210102164 A ARP210102164 A AR P210102164A AR P210102164 A ARP210102164 A AR P210102164A AR 123138 A1 AR123138 A1 AR 123138A1
- Authority
- AR
- Argentina
- Prior art keywords
- antisense strand
- complementarity
- region
- length
- nucleotides
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 title 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 abstract 8
- 239000002773 nucleotide Substances 0.000 abstract 8
- 125000003729 nucleotide group Chemical group 0.000 abstract 8
- 230000008685 targeting Effects 0.000 abstract 4
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 abstract 3
- 101000930020 Homo sapiens Diacylglycerol O-acyltransferase 2 Proteins 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 108091081021 Sense strand Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 229940124447 delivery agent Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un oligonucleótido que comprende: (i) una hebra antisentido que comprende una región de complementariedad a una secuencia de direccionamiento de ACC, en donde la hebra antisentido que comprende una secuencia de nucleótidos seleccionada de SEQ ID Nº 2, 30, 32, 44 y 56; o (ii) una hebra antisentido que comprende una región de complementariedad a una secuencia de direccionamiento de DGAT2, en donde la hebra antisentido comprende una secuencia de nucleótidos seleccionada de SEQ ID Nº 118, 120, 126, 130, 138 y 144. Reivindicación 3: Un oligonucleótido que comprende: (i) una hebra antisentido de 15 - 30 nucleótidos de longitud y una hebra sentido de 15 - 40 nucleótidos de longitud, en donde la hebra antisentido tiene una región de complementariedad a una secuencia de direccionamiento de ACC expuesta en SEQ ID Nº 150 ó 151, y en donde la región de complementariedad es de por lo menos 15 nucleótidos contiguos de longitud; o (ii) una hebra antisentido de 15 - 30 nucleótidos de longitud y una hebra sentido de 15 - 40 nucleótidos de longitud, en donde la hebra antisentido tiene una región de complementariedad a una secuencia de direccionamiento de DGAT2 expuesta en SEQ ID Nº 156 ó 157, y en donde la región de complementariedad es de por lo menos 15 nucleótidos contiguos de longitud. Reivindicación 22: Una composición farmacéutica que comprende el oligonucleótido de cualquiera de las reivindicaciones 1 - 21, y un portador, agente de suministro o excipiente farmacéuticamente aceptable. Reivindicación 23: Una composición que comprende un inhibidor de la expresión de ACC y un inhibidor de la expresión de DGAT2.Claim 1: An oligonucleotide comprising: (i) an antisense strand comprising a region of complementarity to an ACC targeting sequence, wherein the antisense strand comprising a nucleotide sequence selected from SEQ ID Nos. 2, 30, 32, 44 and 56; or (ii) an antisense strand comprising a region of complementarity to a DGAT2 targeting sequence, wherein the antisense strand comprises a nucleotide sequence selected from SEQ ID NOs: 118, 120, 126, 130, 138 and 144. Claim 3 : An oligonucleotide comprising: (i) an antisense strand 15-30 nucleotides in length and a sense strand 15-40 nucleotides in length, wherein the antisense strand has a region of complementarity to an ACC targeting sequence set forth in SEQ ID NO: 150 or 151, and wherein the region of complementarity is at least 15 contiguous nucleotides in length; or (ii) an antisense strand 15-30 nucleotides in length and a sense strand 15-40 nucleotides in length, wherein the antisense strand has a region of complementarity to a DGAT2 targeting sequence set forth in SEQ ID NO: 156 or 157, and wherein the region of complementarity is at least 15 contiguous nucleotides in length. Claim 22: A pharmaceutical composition comprising the oligonucleotide of any of claims 1-21, and a pharmaceutically acceptable carrier, delivery agent or excipient. Claim 23: A composition comprising an inhibitor of ACC expression and an inhibitor of DGAT2 expression.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061045P | 2020-08-04 | 2020-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123138A1 true AR123138A1 (en) | 2022-11-02 |
Family
ID=84578029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102164A AR123138A1 (en) | 2020-08-04 | 2021-08-03 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR123138A1 (en) |
-
2021
- 2021-08-03 AR ARP210102164A patent/AR123138A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529732A5 (en) | ||
| IL290566B2 (en) | Compositions and methods for inhibiting gene expression of lpa | |
| AR066397A1 (en) | COMPOSITIONS OF ARNDS AND METHOD FOR THE TREATMENT OF INFECTIONS BY THE HUMAN PAPILOMA VIRUS (HPV) | |
| JP2016522674A5 (en) | ||
| JP2015523855A5 (en) | ||
| JP2015518712A5 (en) | ||
| PE20120115A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF FACTOR VII GENES | |
| JP2015523853A5 (en) | ||
| PE20210921A1 (en) | ARNI AGENTS AS INHIBITORS OF SERPINE 1 TRANSCRIPTION AND COMPOSITIONS THAT INCLUDE THEM | |
| AR084319A1 (en) | MicroRNA INHIBITORS (miRNA OR miR) THAT INCLUDE BLOCKED NUCLEOTIDES | |
| PE20212248A1 (en) | OLIGOMERIC MOLECULE OF NUCLEIC ACID AND USE OF IT | |
| CU20170001A7 (en) | PHARMACEUTICAL COMPOSITIONS OF NUCLEIC ACID POLYMER PHOSPHOROTIOATE AND NUCLEOSIDE / NUCLEOTIDE ANALOG, USEFUL FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D | |
| PE20230179A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH ANGIOTENSINOGEN (AGT) | |
| AR123420A1 (en) | DUX4 INHIBITORS AND METHODS OF USE THEREOF | |
| FR2790757B1 (en) | OLIGONUCLEOTIDES CONTAINING AN ANTI-SENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. | |
| WO2020099482A3 (en) | Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism | |
| AR123138A1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | |
| CO6660456A2 (en) | Preventive or therapeutic agent against fibrosis | |
| AR079649A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GENES IL-18 | |
| AR125992A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MITOCHONDRIAL AMIDOXIMA REDUCTION COMPONENT 1 (MARC1) | |
| PE20241132A1 (en) | ARNI COMPOSITIONS AND METHODS TO SILENCE ANGIOTENSINOGEN (AGT) | |
| AR123160A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF LPA | |
| AR125230A1 (en) | COMPOSITIONS OF ANTI-HUNTINGTIN (HTT) RNAi AGENTS AND THEIR METHODS OF USE | |
| AR126070A1 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4) | |
| MX2022014496A (en) | Double-stranded oligonucleotide and composition for treating covid-19 containing same. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |